ArticleMethods in molecular biology (Clifton, N.J.)2026
Isolation and Sequencing of Single Circulating Tumor Cells.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Single-cell sequencing (SCS) technology has become an important tool for researchers to study human diseases, including cancer, providing insights into phenotypic and genetic tumor heterogeneity, targeted therapy resistance, and metastasis. SCS technology has proven to be a remarkable tool for shedding light on the impressive molecular heterogeneity of circulating tumor cells (CTCs). However, the extreme rarity and biological heterogeneity of CTCs have imposed technical challenges for their analyses at the single-cell level, and affected the success of robust processing of complex and costly downstream methodologies. Here, we present the entire workflow we developed to enrich, detect and isolate single non-small-cell lung cancer (NSCLC) CTCs to characterize tumor cell subpopulation resistant to targeted therapy. Once isolated, individual CTCs underwent a molecular workflow including whole-genome amplification (WGA) and qualification, followed by two SCS techniques, including targeted next-generation sequencing (NGS) for somatic variant identification and the low-pass whole genome sequencing (LP-WGS) for the analysis of copy number alterations (CNA).
Indexed as
Identifiers
42426460What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.